{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:41:34Z","timestamp":1789684894258,"version":"4.0.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.clml.2021.04.014","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T19:51:45Z","timestamp":1619725905000},"page":"573-579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Genetic Heterogeneity in Chronic Myeloid Leukemia: How Clonal Hematopoiesis and Clonal Evolution May Influence Prognosis, Treatment Outcome, and Risk of Cardiovascular Events"],"prefix":"10.1016","volume":"21","author":[{"given":"Emanuela","family":"Sant'Antonio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Camerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.04.014_bib0001","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.clml.2021.04.014_bib0002","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2021.04.014_bib0003","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0168-9525(93)90209-Z","article-title":"The multistep nature of cancer","volume":"9","author":"Vogelstein","year":"1993","journal-title":"Trends Genet"},{"key":"10.1016\/j.clml.2021.04.014_bib0004","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2021.04.014_bib0005","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.clml.2021.04.014_bib0006","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/344251a0","article-title":"Acute leukaemia in bcr\/abl transgenic mice","volume":"344","author":"Heisterkamp","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.clml.2021.04.014_bib0007","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2021.04.014_bib0008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11899-007-0010-6","article-title":"Genomic instability: the cause and effect of BCR\/ABL tyrosine kinase","volume":"2","author":"Skorski","year":"2007","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2021.04.014_bib0009","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.18632\/oncotarget.806","article-title":"STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia","volume":"3","author":"Warsch","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2021.04.014_bib0010","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.04.014_bib0011","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2021.04.014_bib0012","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0013","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0014","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.04.014_bib0015","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0016","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.clml.2015.02.035","article-title":"Mutations in the BCR-ABL1 kinase domain and elsewhere in chronic myeloid leukemia","volume":"15","author":"Soverini","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.04.014_bib0017","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/asheducation-2005.1.188","article-title":"Pathobiology of lymphoid and myeloid blast crisis and management issues","author":"Ilaria","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2021.04.014_bib0018","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.V95.4.1144.004k04_1144_1150","article-title":"Acquired loss of p53 induces blastic transformation in p210(bcr\/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML","volume":"95","author":"Honda","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0019","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2020004834","article-title":"An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia","volume":"135","author":"Ko","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0020","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.2019004397","article-title":"Preleukemic and leukemic evolution at the stem cell level","volume":"137","author":"Stauber","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0021","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.3390\/ijms20246141","article-title":"Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update","volume":"20","author":"Bavaro","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2021.04.014_bib0022","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/ATVBAHA.119.313353","article-title":"Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care","volume":"40","author":"Manouchehri","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clml.2021.04.014_bib0023","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jacc.2014.06.1186","article-title":"A systematic examination of the 2013 ACC\/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease","volume":"64","author":"Karmali","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clml.2021.04.014_bib0024","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2017-07-794362","article-title":"Clonality in context: hematopoietic clones in their marrow environment","volume":"130","author":"Cooper","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0025","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","article-title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","volume":"130","author":"Zink","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0026","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.04.014_bib0027","first-page":"258","article-title":"Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms","volume":"4","author":"Anger","year":"1990","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.04.014_bib0028","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.04.014_bib0029","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1182\/bloodadvances.2018020222","article-title":"Clinical consequences of clonal hematopoiesis of indeterminate potential","volume":"2","author":"Steensma","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.04.014_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2019.08.004","article-title":"Biological implications of clonal hematopoiesis","volume":"77","author":"Luis","year":"2019","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2021.04.014_bib0031","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jamacardio.2019.0302","article-title":"Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review","volume":"4","author":"Calvillo-Arguelles","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clml.2021.04.014_bib0032","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.clml.2021.04.014_bib0033","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.04.014_bib0034","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.25306","article-title":"Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY","volume":"94","author":"Hehlmann","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.04.014_bib0035","doi-asserted-by":"crossref","first-page":"12484","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2021.04.014_bib0036","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.leukres.2006.11.009","article-title":"Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference","volume":"31","author":"Valent","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.04.014_bib0037","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0038","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1182\/blood-2015-08-663237","article-title":"Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression","volume":"126","author":"Cargo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0039","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","article-title":"MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance","volume":"126","author":"Kwok","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0040","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.04.014_bib0041","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/leu.2016.163","article-title":"Subtype-specific patterns of molecular mutations in acute myeloid leukemia","volume":"31","author":"Rose","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.04.014_bib0042","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/leu.2014.211","article-title":"Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis","volume":"28","author":"Corces-Zimmerman","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.04.014_bib0043","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12185-015-1870-5","article-title":"Aging, clonal hematopoiesis and preleukemia: not just bad luck?","volume":"102","author":"Shlush","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2021.04.014_bib0044","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/ijms20030789","article-title":"Clonal hematopoiesis with oncogenic potential (CHOP): separation from CHIP and roads to AML","volume":"20","author":"Valent","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2021.04.014_bib0045","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0046","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and atherosclerosis","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.04.014_bib0047","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41375-018-0047-7","article-title":"Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis","volume":"32","author":"Arends","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.04.014_bib0048","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature21505","article-title":"Cardiovascular disease: commonality with cancer","volume":"543","author":"Tall","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.clml.2021.04.014_bib0049","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.exphem.2019.12.006","article-title":"Clonal hematopoiesis, aging, and cardiovascular diseases","volume":"83","author":"Pardali","year":"2020","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2021.04.014_bib0050","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/CIRCGENETICS.113.000441","article-title":"DNA methylation map of human atherosclerosis","volume":"7","author":"Zaina","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.clml.2021.04.014_bib0051","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2021.04.014_bib0052","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2021.04.014_bib0053","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.clml.2021.04.014_bib0054","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clml.2021.04.014_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2016.07.002","article-title":"Transcription factor defects causing platelet disorders","volume":"31","author":"Daly","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2021.04.014_bib0056","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3324\/haematol.2019.235994","article-title":"Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding","volume":"105","author":"Veninga","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.04.014_bib0057","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ajhg.2017.05.013","article-title":"Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life","volume":"101","author":"Acuna-Hidalgo","year":"2017","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clml.2021.04.014_bib0058","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","article-title":"Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease","volume":"17","author":"Jaiswal","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.clml.2021.04.014_bib0059","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0060","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases","volume":"95","author":"Sant'Antonio","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.04.014_bib0061","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.04.014_bib0062","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.04.014_bib0063","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","article-title":"High-risk additional chromosomal abnormalities at low blast counts herald death by CML","volume":"34","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.04.014_bib0064","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/bloodadvances.2017011858","article-title":"Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy","volume":"1","author":"Gong","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.04.014_bib0065","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0066","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","article-title":"Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority","volume":"101","author":"Bumm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0067","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/cncr.11729","article-title":"Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"98","author":"Medina","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.04.014_bib0068","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1038\/bcj.2017.36","article-title":"Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia","volume":"7","author":"Togasaki","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.04.014_bib0069","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.04.014_bib0070","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","article-title":"Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors","volume":"104","author":"Nteliopoulos","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.04.014_bib0071","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Adnan Awad","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.04.014_bib0072","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0073","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1172\/JCI109193","article-title":"Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells","volume":"62","author":"Fialkow","year":"1978","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2021.04.014_bib0074","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2011.139","article-title":"Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia","volume":"25","author":"Roche-Lestienne","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.04.014_bib0075","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/leu.2010.236","article-title":"IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis","volume":"25","author":"Soverini","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.04.014_bib0076","first-page":"1619","article-title":"Cardiovascular scoring and age-related mutations predict the occurrence of adverse vascular events in CML patients during nilotinib therapy","volume":"130","author":"Hadzijusufovic","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.014_bib0077","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?","volume":"105","author":"Atallah","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.04.014_bib0078","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/bloodadvances.2019000865","article-title":"Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP","volume":"3","author":"Baccarani","year":"2019","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:58Z","timestamp":1761870958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021001750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2152265021001750"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.04.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic Heterogeneity in Chronic Myeloid Leukemia: How Clonal Hematopoiesis and Clonal Evolution May Influence Prognosis, Treatment Outcome, and Risk of Cardiovascular Events","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}